Related Experiment Video
Updated: Jul 14, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Cardiac arrhythmias: drugs and devices
1Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA. jatlee@mcw.edu
Current Opinion in Anaesthesiology
|October 4, 2006
Summary
This review covers therapies for preventing and treating perioperative cardiac arrhythmias, including new drug classes, devices, and managing potassium imbalances to improve patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Medical Devices
Background:
- Perioperative cardiac arrhythmias pose significant risks to patient outcomes.
- Understanding arrhythmogenesis and pro-arrhythmia is crucial for effective management.
- Existing therapies require continuous evaluation and improvement.
Purpose of the Study:
- To review current remedial therapies for perioperative cardiac arrhythmias.
- To discuss novel concepts in arrhythmia generation and management.
- To highlight advancements in antiarrhythmic drugs and cardiac rhythm devices.
Main Methods:
- Comprehensive literature review of existing studies and clinical trials.
- Analysis of new concepts in cardiac electrophysiology and pharmacology.
- Evaluation of the efficacy and safety of various therapeutic interventions.
Main Results:
- Newer, selective class 3 antiarrhythmic drugs show promise.
- Cardiac rhythm management devices offer effective solutions for certain arrhythmias.
- Intravenous amiodarone is effective for destabilizing ventricular arrhythmias.
- Preoperative potassium imbalance management is vital.
Conclusions:
- A multi-faceted approach involving pharmacotherapy and device therapy is essential.
- Continued research into novel antiarrhythmic strategies is warranted.
- Personalized therapeutic strategies based on patient-specific factors are key.
More Related Videos
Related Concept Videos
01:28Mechanism of Cardiac Arrhythmias
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:29Disturbances in Heart Rhythm
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...